<DOC>
	<DOCNO>NCT02166697</DOCNO>
	<brief_summary>The purpose survey design investigate treatment status hypertensive patient metabolic syndrome-related risk factor treat candesartan cilexetil tablet ( Blopress Tablets ) , well assess relationship risk factor ( example , visceral fat accumulation ) incidence cerebrovascular/cardiovascular event exploratory manner .</brief_summary>
	<brief_title>Blopress Tablets Specified Drug-use Survey `` Hypertension : Survey Patients With Metabolic Syndrome ''</brief_title>
	<detailed_description>This survey design investigate treatment status hypertensive patient metabolic syndrome-related risk factor treat candesartan cilexetil tablet ( Blopress Tablets ) , well assess relationship risk factor ( example , visceral fat accumulation ) incidence cerebrovascular/cardiovascular event exploratory manner . For adult , 4-8 mg candesartan cilexetil typically administer orally daily . The dose increase 12 mg , necessary . For patient complication renal damage , however , administration candesartan cilexetil start 2 mg daily , , necessary , dose increase 8 mg .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Hypertensive patient least one follow risk factor : Waist circumference great equal ( ≥ ) 85 centimeter ( cm ) male ≥ 90 cm female Fasting triglyceride level ≥ 150 milligram per deciliter ( mg/dL ) Highdensity lipoprotein ( HDL ) cholesterol level le ( &lt; ) 40 mg/dL Fasting blood glucose level ≥ 110 mg/dL Bodymass index ( BMI ) ≥ 25.0 * Patients currently take medication hypertriglyceridemia , hypoHDLcholesterolemia , diabetes mellitus also regard meeting criterion inclusion surveillance Hypertensive patient meet following condition ( [ 1 ] [ 3 ] ) : 1 . Patients receive continuous therapy Blopress Tablets 2 . Patients age &lt; 20 year ≥ 75 year 3 . Patients history cerebrovascular coronary artery disease within 6 month start surveillance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>